MicroRNA‑200a suppresses migration and invasion and enhances the radiosensitivity of NSCLC cells by inhibiting the HGF/c‑Met signaling pathway.


Journal

Oncology reports
ISSN: 1791-2431
Titre abrégé: Oncol Rep
Pays: Greece
ID NLM: 9422756

Informations de publication

Date de publication:
Mar 2019
Historique:
received: 01 05 2018
accepted: 28 11 2018
pubmed: 21 12 2018
medline: 6 3 2019
entrez: 21 12 2018
Statut: ppublish

Résumé

Hepatocyte growth factor (HGF), an activator of the c‑Met signaling pathway, is involved in tumor invasiveness, metastasis and radiotherapy resistance. In the present study, a novel HGF regulatory pathway in lung cancer involving micro-RNAs (miRNAs/miR) is described. Immunohistochemical staining and western blot analyses demonstrated that HGF was upregulated and associated with miR‑200a downregulation in non‑small cell lung cancer (NSCLC) samples compared with normal lung tissues. The association between HGF and miR‑200a was associated with the degree of tumor malignancy and cell migration and invasion. miR‑200a negatively regulated HGF expression by targeting the 3'‑untranslated region of the HGF mRNA. miR‑200a overexpression induced HGF downregulation, decreased NSCLC cell migration and invasion, promoted apoptosis, and decreased cell survival in A549 and H1299 cells in response to ionizing radiation. The present results revealed a previously uncharacterized role of miRNA‑200a in regulating tumor malignancy and radiosensitivity by suppressing HGF expression, a key factor in the HGF/c‑Met pathway.

Identifiants

pubmed: 30569179
doi: 10.3892/or.2018.6925
pmc: PMC6365696
doi:

Substances chimiques

HGF protein, human 0
MIRN200 microRNA, human 0
MicroRNAs 0
Hepatocyte Growth Factor 67256-21-7
MET protein, human EC 2.7.10.1
Proto-Oncogene Proteins c-met EC 2.7.10.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1497-1508

Références

Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
J Dermatol Sci. 2002 Nov;30(2):108-15
pubmed: 12413766
Cancer Res. 2003 Nov 15;63(22):7926-35
pubmed: 14633723
Cell. 2004 Jan 23;116(2):281-97
pubmed: 14744438
Cell. 2005 Jan 14;120(1):15-20
pubmed: 15652477
Mayo Clin Proc. 2008 May;83(5):584-94
pubmed: 18452692
Scand J Gastroenterol. 2008 Mar;43(3):289-98
pubmed: 18938767
Nat Rev Genet. 2009 Oct;10(10):704-14
pubmed: 19763153
Oncol Rep. 2010 Jan;23(1):141-50
pubmed: 19956874
Neoplasia. 2009 Dec;11(12):1292-300
pubmed: 20019837
J Physiol Biochem. 2011 Mar;67(1):129-39
pubmed: 20981514
J Natl Cancer Inst. 2011 Apr 20;103(8):645-61
pubmed: 21464397
Future Oncol. 2011 Sep;7(9):1045-55
pubmed: 21919692
Int J Oncol. 2012 Feb;40(2):583-91
pubmed: 21922134
Head Neck. 2011 Oct;33(10):1458-66
pubmed: 21928418
Ann Thorac Cardiovasc Surg. 2012;18(1):1-7
pubmed: 21959198
Nat Med. 2011 Nov 20;17(12):1627-35
pubmed: 22101765
Nat Rev Cancer. 2011 Nov 24;11(12):849-64
pubmed: 22113163
J Cell Biochem. 2012 May;113(5):1451-9
pubmed: 22213511
Clin Cancer Res. 2012 Apr 15;18(8):2269-77
pubmed: 22374333
Nat Rev Clin Oncol. 2012 May 08;9(6):314-26
pubmed: 22566105
Front Biosci (Landmark Ed). 2012 Jun 01;17:2508-40
pubmed: 22652795
Expert Opin Biol Ther. 2012 Sep;12(9):1221-39
pubmed: 22731874
J Clin Oncol. 2012 Sep 10;30(26):3287-96
pubmed: 22869872
Cancer. 2013 May 15;119(10):1768-75
pubmed: 23423860
Front Oncol. 2013 Apr 08;3:74
pubmed: 23579692
Cancer J. 2013 Jul-Aug;19(4):316-23
pubmed: 23867513
Jpn J Clin Oncol. 2013 Oct;43(10):945-53
pubmed: 24014883
Eur J Med Res. 2013 Nov 12;18:41
pubmed: 24216130
Oncogene. 2015 Jan 22;34(4):413-23
pubmed: 24469061
Mol Ther. 2014 Aug;22(8):1494-1503
pubmed: 24791940
Mol Cancer. 2014 Jul 06;13:166
pubmed: 24997798
Oncotarget. 2014 Aug 15;5(15):6113-29
pubmed: 25026294
Histopathology. 2014 Nov;65(5):684-92
pubmed: 25039982
Cell Signal. 2014 Nov;26(11):2381-9
pubmed: 25049078
Elife. 2014 Dec 10;3:null
pubmed: 25490933
CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29
pubmed: 25559415
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
PLoS One. 2015 Sep 17;10(9):e0138366
pubmed: 26379276
Cancer Sci. 2016 Apr;107(4):407-16
pubmed: 26790028
CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32
pubmed: 26808342
Clin Transl Med. 2014 Dec;3(1):30
pubmed: 26932375
Oncotarget. 2016 Jun 14;7(24):37145-37159
pubmed: 27175600
Oncotarget. 2016 Jul 26;7(30):48432-48442
pubmed: 27374174
Cell Biochem Biophys. 2018 Jun;76(1-2):135-145
pubmed: 28852971
J Gastroenterol. 2018 Jun;53(6):725-739
pubmed: 29103082
Oncogene. 2018 May;37(21):2890-2902
pubmed: 29520106
Molecules. 2018 Jun 26;23(7):null
pubmed: 29949931
J Cell Physiol. 2018 Dec;233(12):9447-9457
pubmed: 30136280
Clin Cancer Res. 2019 Jan 15;25(2):663-673
pubmed: 30201763
J Transl Med. 2018 Sep 12;16(1):253
pubmed: 30208970

Auteurs

Menghua Du (M)

Department of Oncology and Radiotherapy, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215123, P.R. China.

Jin Wang (J)

Department of Oncology and Radiotherapy, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215123, P.R. China.

Huan Chen (H)

Department of Oncology and Radiotherapy, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215123, P.R. China.

Shouli Wang (S)

Department of Pathology, School of Biology and Basic Medical Sciences, Soochow University, Suzhou, Jiangsu 215123, P.R. China.

Liesong Chen (L)

Department of Oncology and Radiotherapy, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215123, P.R. China.

Yichang Xu (Y)

Department of Pathology, School of Biology and Basic Medical Sciences, Soochow University, Suzhou, Jiangsu 215123, P.R. China.

Fengtao Su (F)

Cancer Institute, Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, P.R. China.

Xueguan Lu (X)

Department of Oncology and Radiotherapy, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215123, P.R. China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH